SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Paracelsian Inc (PRLN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Richard Mazzarella who wrote (485)9/16/1996 7:55:00 AM
From: WWS   of 4342
 
Richard, Agouron appears to be in a fix: a small company late to market with a "me too" protease inhibitor. Main benefit over standard therapies appears to be fewer side effects. That they haven't found a big time market partner for US rollout is a telling point. Also of interest, though, is the possibility that some AIDS patients may have already "failed" on the new three prong drug regime. Wonder whether this is due already to virus having developed resistance, or simply to certain individual patients being "too far along" to benefit from this treatment regime. Otherwise, I see no specific implication of this announcement for PRLN, do you? Bill in St. Louis.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News